Immune drug shows promise in slowing return of prostate cancer

NCT ID NCT03637543

Ongoing Disease control Sponsor: Beth Israel Deaconess Medical Center Source: ClinicalTrials.gov ↗

First seen May 27, 2026 · Last updated Jun 10, 2026 · Updated 6 times

Summary

This study tests the immune drug nivolumab in 29 men whose prostate cancer has returned after initial treatment, shown by rising PSA levels. The goal is to see if the drug can stabilize or lower PSA and keep the cancer from growing for at least 12 weeks. Participants receive nivolumab infusions and are monitored for side effects and cancer progression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
DFCI Londonderry

Londonderry, New Hampshire, 03053, United States
DFCI South Shore

South Weymouth, Massachusetts, 02190, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
St. Elizabeth's Medical Center

Boston, Massachusetts, 02135, United States

Conditions

Explore the condition pages connected to this study.

PROSTATE CANCER